CDC/AHA Workshop on Markers of Inflammation and Cardiovascular Disease: Application to Clinical and Public Health Practice: Overview

CDC STACKS serves as an archival repository of CDC-published products including scientific findings, journal articles, guidelines, recommendations, or other public health information authored or co-authored by CDC or funded partners. As a repository, CDC STACKS retains documents in their original published format to ensure public access to scientific information.

Up-to-date Information

Up-to-Date Info: To find the latest CDC information on this topic go to: https://doi.org/10.1161/01.CIR.0000148979.11121.6B

CDC/AHA Workshop on Markers of Inflammation and Cardiovascular Disease: Application to Clinical and Public Health Practice: Overview

December 21 2004
By American Heart Association. ...
Source: Circulation. 2004; 110(25):e545-9.

English

Details Related Documents You May Also Like

Details:

Corporate Authors:

American Heart Association. ; Centers for Disease Control and Prevention (U.S.)

American Heart Association. ; Centers for Disease Control and Prevention (U.S.) Less -
Description:

The Centers for Disease Control and Prevention/American Heart Association (CDC/AHA) Workshop on Markers of Inflammation and Cardiovascular Disease: Application to Clinical and Public Health Practice was convened on March 14 and 15, 2002, to examine the use of inflammatory markers in patients who are at risk for cardiovascular disease (CVD). The goal of the workshop was to determine which of the available tests, if any, should be used; what results should be used to define high risk; which patients should be tested; and the indications for which the tests would be most useful. To achieve this goal, the workshop participants set down 5 objectives: 1.To review the growing body of scientific evidence from diverse sources and examine the association between several inflammatory markers and CVD, including the strength, consistency, independence, and generalizability of the data; 2. To consider the clinical testing and various assays of inflammatory markers and identify which may be the best assay to use in identifying individuals at risk; 3. To identify areas in which questions persist to foster additional research; 4. To recommend which tests should be performed for which patients and in which clinical settings for the purpose of risk stratification, therapeutic monitoring, and other clinical applications, on the basis of scientific evidence; and, 5. To explore the public health implications of an association between inflammatory markers and CVD.
Subjects:

[+]

Acute-Phase Proteins Biological Markers C-Reactive Protein Cardiovascular Diseases Cell Adhesion Molecules Chemokines Cytokines Diagnosis, Differential Diagnostic Tests, Routine Humans Inflammation Public Health Practice Risk Assessment Specimen Handling
Source:

Circulation. 2004; 110(25):e545-9.
Pubmed ID:

15611379
Document Type:

Journal Article
Volume:

110
Issue:

25
Collection(s):

Guidelines and Recommendations
Main Document Checksum:

[+]

urn:sha-512:bd4d230cc80390236e8cbbaade474f27d61bae42d7c1a33c4923804690babaa4ef0c4e7594ab779a4a1dc2386025b2d3d250ec485c7230a5da63e3a397566be8
Download URL:

https://stacks.cdc.gov/view/cdc/177368/cdc_177368_DS1.pdf
File Type:

[PDF-102.35 KB]